UroGen Pharma (URGN) 10-Q 4 Aug 21 2021 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2021	Jul. 27, 2021
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2021
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q2
Trading Symbol	URGN
Title of 12(b) Security	Ordinary Shares, par value NIS 0.01 per share
Security Exchange Name	NASDAQ
Entity Registrant Name	UROGEN PHARMA LTD.
Entity Central Index Key	0001668243
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Common Stock, Ordinary Shares Outstanding		22,363,023
Entity Shell Company	false
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Document Quarterly Report	true
Document Transition Report	false
Entity File Number	001-38079
Entity Incorporation, State or Country Code	L3
Entity Tax Identification Number	98-1460746
Entity Address, Address Line One	400 Alexander Park Drive
Entity Address, City or Town	Princeton
Entity Address, State or Province	NJ
Entity Address, Postal Zip Code	08540
City Area Code	646
Local Phone Number	768-9780

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (unaudited) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 63,322	$ 52,864
Marketable securities	57,710	49,154
Restricted cash	1,225	1,226
Accounts receivable	9,512	7,047
Inventories	3,421	1,964
Prepaid expense and other current assets	5,308	3,364
Total current assets	140,498	115,619
Non-current assets:
Property and equipment, net	2,001	2,046
Restricted deposit	223	223
Right of use asset	1,653	2,158
Marketable securities	8,290	1,893
Other non-current assets	1,103	66
Total Assets	153,768	122,005
Current liabilities:
Accounts payable and accrued expense	10,342	10,023
Employee related accrued expense	6,773	9,554
Other current liabilities	1,941	1,859
Total current liabilities:	19,056	21,436
Non-current liabilities:
Prepaid forward obligation	74,802
Long-term lease liability	922	1,497
Uncertain tax positions liability	2,717	2,717
Total Liabilities	97,497	25,650
Commitments and contingencies (Note 14)
Shareholders' equity:
Ordinary shares, NIS 0.01 par value; 100,000,000 shares authorized at June 30, 2021 and December 31, 2020; 22,354,533 and 22,167,791 shares issued and outstanding as of June 30, 2021 and December 31, 2020, respectively	61	60
Additional paid-in capital	464,823	452,525
Accumulated deficit	(408,658)	(356,501)
Accumulated other comprehensive income	45	271
Total Shareholders' Equity	56,271	96,355
Total Liabilities and Shareholders' Equity	$ 153,768	$ 122,005

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) (unaudited) - ₪ / shares	Jun. 30, 2021	Dec. 31, 2020
Statement Of Financial Position [Abstract]
Ordinary shares, par value	₪ 0.01	₪ 0.01
Ordinary shares, shares authorized	100,000,000	100,000,000
Ordinary shares, issued	22,354,533	22,167,791
Ordinary shares, outstanding	22,354,533	22,167,791

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Income Statement [Abstract]
Revenue	$ 13,032	$ 372	$ 20,517	$ 372
Cost of revenue	1,427	48	2,324	48
Gross profit	11,605	324	18,193	324
Operating expense:
Research and development expense	12,124	8,106	22,637	24,694
Selling, general and administrative expense	22,304	24,018	44,493	45,991
Operating loss	(22,823)	(31,800)	(48,937)	(70,361)
Financing on prepaid forward obligation	(3,120)		(3,120)
Interest and other income, net	33	451	212	1,219
Loss before income taxes	(25,910)	(31,349)	(51,845)	(69,142)
Income tax expense	312		312
Net Loss	(26,222)	(31,349)	(52,157)	(69,142)
Statements of Comprehensive Loss
Net loss	(26,222)	(31,349)	(52,157)	(69,142)
Other comprehensive income
Unrealized (loss) gain on marketable securities	(98)	449	(226)	484
Comprehensive Loss	$ (26,320)	$ (30,900)	$ (52,383)	$ (68,658)
Net loss per ordinary share basic and diluted	$ (1.17)	$ (1.44)	$ (2.34)	$ (3.22)
Weighted average number of shares outstanding used in computation of basic and diluted loss per ordinary share	22,331,119	21,753,001	22,287,037	21,454,341

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Shareholders' Equity (unaudited) - USD ($) $ in Thousands	Total	Ordinary Shares	Additional Paid-In Capital	Accumulated Deficit	Other Comprehensive Income (Loss)
Balance at Dec. 31, 2019	$ 180,302	$ 57	$ 407,986	$ (228,017)	$ 276
Balance,Share at Dec. 31, 2019		21,026,184
Exercise of options into ordinary shares	503	$ 1	502
Exercise of options into ordinary shares, shares		275,112
Share-based compensation	14,736		14,736
Issuance of ordinary shares, net of issuance expenses	15,777	$ 2	15,775
Issuance of ordinary shares, net of issuance expenses, shares		700,000
Other comprehensive income (loss)	484				484
Net loss	(69,142)			(69,142)
Balance at Jun. 30, 2020	142,660	$ 60	438,999	(297,159)	760
Balance,Share at Jun. 30, 2020		22,001,296
Balance at Mar. 31, 2020	150,454	$ 58	415,895	(265,810)	311
Balance,Share at Mar. 31, 2020		21,212,940
Exercise of options into ordinary shares	210		210
Exercise of options into ordinary shares, shares		88,356
Share-based compensation	7,119		7,119
Issuance of ordinary shares, net of issuance expenses	15,777	$ 2	15,775
Issuance of ordinary shares, net of issuance expenses, shares		700,000
Other comprehensive income (loss)	449				449
Net loss	(31,349)			(31,349)
Balance at Jun. 30, 2020	142,660	$ 60	438,999	(297,159)	760
Balance,Share at Jun. 30, 2020		22,001,296
Balance at Dec. 31, 2020	96,355	$ 60	452,525	(356,501)	271
Balance,Share at Dec. 31, 2020		22,167,791
Exercise of options into ordinary shares	58	$ 1	57
Exercise of options into ordinary shares, shares		186,742
Share-based compensation	12,241		12,241
Other comprehensive income (loss)	(226)				(226)
Net loss	(52,157)			(52,157)
Balance at Jun. 30, 2021	56,271	$ 61	464,823	(408,658)	45
Balance,Share at Jun. 30, 2021		22,354,533
Balance at Mar. 31, 2021	76,491	$ 61	458,723	(382,436)	143
Balance,Share at Mar. 31, 2021		22,280,394
Exercise of options into ordinary shares	54		54
Exercise of options into ordinary shares, shares		74,139
Share-based compensation	6,046		6,046
Other comprehensive income (loss)	(98)				(98)
Net loss	(26,222)			(26,222)
Balance at Jun. 30, 2021	$ 56,271	$ 61	$ 464,823	$ (408,658)	$ 45
Balance,Share at Jun. 30, 2021		22,354,533

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flow (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Cash Flows From Operating Activities
Net loss	$ (52,157)	$ (69,142)
Adjustment to reconcile net loss to net cash from operating activities:
Depreciation and amortization	401	178
Accrued financing on prepaid forward obligation	2,330
Amortization on marketable securities	181	234
Stock-based compensation	12,241	14,736
Amortization of right of use asset	469	753
Lease liability	(652)	(748)
Changes in operating assets and liabilities:
Inventory	(1,457)	(1,125)
Accounts receivable	(2,465)	(402)
Prepaid expense and other current assets	(1,944)	(1,035)
Other non-current assets	(1,026)
Accounts payable and accrued expense	319	(2,046)
Employee related accrued expense	(2,781)	(967)
Other current liabilities	195
Net cash used in operating activities	(46,346)	(59,564)
Cash Flows From Investing Activities
Purchases of marketable securities	(41,655)	(29,688)
Maturities of marketable securities	26,295	60,610
Purchases of property and equipment	(356)	(383)
Net cash (used in) provided by investing activities	(15,716)	30,539
Cash Flows From Financing Activities
Proceeds from prepaid forward arrangement	72,472	503
Proceeds from exercise of options into ordinary shares	58
Issuances of ordinary shares, net of issuance expense		15,885
Issuance cost related to at-the-market issuances	(11)
Net cash provided by financing activities	72,519	16,388
Increase (Decrease) in Cash and Cash Equivalents	10,457	(12,637)
Cash, Cash Equivalents and Restricted Cash at Beginning of Period	54,090	50,211
Cash, Cash Equivalents and Restricted Cash at End of Period	64,547	37,574
Supplemental Disclosures of Non-Cash Activities
Non-cash purchases of property and equipment		219
Non-cash new lease liabilities	$ (36)	29
Non-cash issuance cost		$ 32

Business and Nature of Operatio

Business and Nature of Operations	6 Months Ended
	Jun. 30, 2021
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Business and Nature of Operations	Note 1 – Business and Nature of Operations Nature of Operations UroGen 0 UroGen wholly owned a n UPL o l g Jelmyto On April 15, 2020, the U.S. Food and Drug Administration (“FDA”) granted expedited approval for Jelmyto Jelmyto RTGel

Basis of Presentation

Basis of Presentation	6 Months Ended
	Jun. 30, 2021
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Basis of Presentation	Note 2 – Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all the information and footnotes required by GAAP for complete financial statements. In the opinion of the Company’s management, the accompanying condensed consolidated financial statements contain all adjustments (consisting of normal recurring accruals and adjustments) necessary for fair statement of its financial position, results of operations and cash flows of the Company at the dates and for the periods indicated. Interim results are not necessarily indicative of results for the full fiscal year. The year-end condensed consolidated balance sheet data was derived from audited financial statements but does not include all disclosures required by accounting principles generally accepted in the United States. The unaudited condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and the notes thereto contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020, as filed with the Securities and Exchange Commission (“SEC”) on March 18, 2021. The consolidated financial statements include the accounts of UPL and its wholly owned subsidiary UPI. Intercompany balances and transactions have been eliminated during consolidation. The Company has experienced net losses since its inception and has an accumulated deficit of $408.7 million and $356.5 million as of June 30, 2021 and December 31, 2020, respectively. The Company expects to incur losses and have negative net cash flows from operating activities as it executes on its strategy including engaging in further research and development activities, particularly conducting non-clinical studies and clinical trials. The success of the Company depends on the ability to successfully commercialize its technologies to support its operations and strategic plan. Based on management’s cash flow projections the Company believes that its cash and cash equivalents and marketable securities are sufficient to fund the Company’s planned operations for at least the next 12 months. The Company anticipates that it may need to raise additional capital in the future. There can be no assurances that the Company will be able to secure such additional financing if at all, or at terms that are satisfactory to the Company, and that it will be sufficient to meet its needs. In the event the Company is not successful in obtaining sufficient funding, this could force us to delay, limit, or reduce our product development, commercialization efforts or other operations.

Significant Accounting Policies

Significant Accounting Policies	6 Months Ended
	Jun. 30, 2021
Accounting Policies [Abstract]
Significant Accounting Policies	Note 3 – Significant Accounting Policies Principles of Consolidation The condensed consolidated financial statements include the accounts of UPL and its subsidiary, UPI. Intercompany balances and transactions have been eliminated during consolidation. Use of Estimates The U.S. a i i n a critical estimates relate i Functional The p l Accordingly, l n i a condensed Cash and Cash Equivalents; Marketable Securities The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents. Cash and cash equivalents consist primarily of money market funds and bank money market accounts and are stated at cost, which approximates fair value. Cash and cash equivalents and marketable securities totaled $129.3 million as of June 30, 2021. The Company classifies its marketable securities as available-for-sale in accordance with the Financial Accounting Standards Board (“ Short-term investments are valued using models or other valuation methodologies that use Level 2 inputs. These models are primarily industry-standard models that consider various assumptions, including time value, yield curve, volatility factors, default rates, current market and contractual prices for the underlying financial instruments, as well as other relevant economic measures. The majority of these assumptions are observable in the marketplace, can be derived from observable data or are supported by observable levels at which transactions are executed in the marketplace. For individual debt securities classified as available-for-sale securities where there has been a decline in fair value below amortized cost, the Company determines whether the decline resulted from a credit loss or other factors. The Company records impairment relating to credit losses through an allowance for credit losses, limited by the amount that the fair value is less than the amortized cost basis. Impairment that has not been recorded through an allowance for credit losses is recorded through other comprehensive income, net of applicable taxes. Concentration of Credit Risk Financial instruments, which potentially subject the Company to significant concentrations of credit risk, consist primarily of cash and cash equivalents and marketable securities. The primary objectives for the Company ’ The Company ’ The Company’s product sales are recognized through the Company's arrangement with a single customer, a third-party national specialty distributor. The Company assesses the need for an allowance for doubtful accounts primarily based on creditworthiness, historical payment experience and general economic conditions. The Company has not experienced any credit losses related to this customer and has not currently recognized any allowance for doubtful accounts. Income Taxes The Company provides for income taxes based on pretax income, if any, and applicable tax rates available in the various jurisdictions in which it operates, including Israel and the U.S. deferred l e n s a a The n Inventory The Company capitalizes inventory costs related to products to be sold in the ordinary course of business. The Company makes a determination of capitalizing inventory costs for a product based on, among other factors, status of regulatory approval, information regarding safety, efficacy and expectations relating to commercial sales and recoverability of costs. For Jelmyto The Company values its inventory at the lower of cost or net realizable value. The Company measures inventory approximating actual cost under a first-in, first-out basis. The Company assesses recoverability of inventory each reporting period to determine any write down to net realizable value resulting from excess or obsolete inventories . Property and Equipment Property and equipment are recorded at historical cost, net of accumulated depreciation, amortization and, if applicable, impairment charges. The Company reviews its property and equipment assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Property and equipment are depreciated over the following useful lives (in years): Useful Lives Computers and software 3 Laboratory equipment 3-6.5 Furniture 5-16.5 Manufacturing equipment 2 Leasehold improvements are amortized on a straight-line basis over the shorter of their estimated useful lives or lease terms. See Note 8 for further discussion regarding property and equipment. Prepaid Forward Obligation The Company is party to a transaction with RTW Investments (the “RTW Transaction”) in which the Company received funds to support the continued launch of Jelmyto Jelmyto Leases The Company is a lessee in several noncancelable operating leases, primarily for office space, office equipment and vehicles. The Company currently has no finance leases. The Company accounts for leases in accordance with ASC Topic 842, “Leases” . Lease expense is recognized on a straight-line basis for operating leases. Variable lease payments associated with the Company’s leases are recognized when the event, activity, or circumstance in the lease agreement on which those payments are assessed occurs. Variable lease payments are presented as operating expense on the condensed consolidated statements of operations in the same line item as expense arising from fixed lease payments. The Company’s lease terms may include options to extend the lease. The lease extensions are included in the measurement of the right of use asset and lease liability when it is reasonably certain that it will exercise that option. Because most of the Company’s leases do not provide an implicit rate of return, an incremental borrowing rate is used based on the information available at the commencement date in determining the present value of lease payments on an individual lease basis. The Company’s incremental borrowing rate for a lease is the rate of interest it would have to pay on a collateralized basis to borrow an amount equal to the lease payments under similar terms. ROU assets for operating leases are periodically reviewed for impairment losses under ASC 360-10, “Property, Plant, and Equipment”, to determine whether an ROU asset is impaired, and if so, the amount of the impairment loss to recognize. Revenue Product sales from Jelmyto Jelmyto Research and Development Expense Research and development costs are expensed as incurred and consist primarily of the cost of salaries, share-based compensation expense, payroll taxes and other employee benefits, subcontractors and materials used for research and development activities, including nonclinical studies, clinical trials, manufacturing costs and professional services. The costs of services performed by others in connection with the research and development activities of the Company, including research and development conducted by others on behalf of the Company, shall be included in research and development costs and expensed as the contracted work is performed. The Company accrues for costs incurred as the services are being provided by monitoring the status of the trial or project and the invoices received from its external service providers. The Company adjusts its accrual as actual costs become known. Where contingent milestone payments are due to third parties under research and development arrangements or license agreements, the milestone payment obligations are expensed when the milestone results are achieved. Selling General and Administrative Expense Selling, general and administrative expense consists primarily of personnel costs (including share-based compensation related to directors, employees and consultants). Other significant costs include commercial, medical affairs, external professional service costs, facility costs, accounting and audit services, legal services, and other consulting fees. Selling, general and administrative costs are expensed as incurred, and the Company accrues for services provided by third parties related to the above expenses by monitoring the status of services provided and receiving estimates from its service providers and adjusting its accruals as actual costs become known. Share-Based Compensation Share-based compensation cost is measured at the grant date based on the fair value of the award and is recognized as expense over the required service period, which is equal to the vesting period. The fair value of options is determined using the Black-Scholes option-pricing model. The fair value of a restricted stock unit (“RSU”) equaled the closing price of the Company’s ordinary shares on the grant date. The Company accounts for forfeitures as they occur in accordance with ASC Topic 718, “Compensation—Stock Compensation”. The s n g Net Loss per Ordinary Share Basic net loss per share is computed by dividing the net loss attributable to ordinary shareholders by the weighted-average number of ordinary shares outstanding. Diluted net loss per share is computed similarly to basic net loss per share except that the denominator is increased to include the number of additional ordinary shares that would have been outstanding if the potential ordinary shares had been issued and if the additional ordinary shares were dilutive. For all periods presented, potentially dilutive securities are excluded from the computation of fully diluted loss per share as their effect is anti-dilutive. Recently Issued Accounting Pronouncements The Company has reviewed the Accounting Standards Updates recently issued by the Financial Accounting Standards Board, and determined that they are not applicable to the Company.

Other Financial Information

Other Financial Information	6 Months Ended
	Jun. 30, 2021
Other Financial Information [Abstract]
Other Financial Information	Note 4 – Other Financial Information Accounts Payable and Accrued Expense Accounts payable and accrued expense consists of the following as of June 30, 2021 and December 31, 2020 (in thousands): June 30, 2021 December 31, 2020 Accounts payable $ 4,830 $ 3,271 Accrued sales reserves 712 382 Accrued clinical expense 1,256 1,359 Accrued research and development expense 859 1,356 Accrued selling, general and administrative expense 1,585 2,440 Accrued other expense 1,100 1,215 Total accounts payable and accrued expense $ 10,342 $ 10,023 Interest and Other Income (Expense), Net Interest and other income (expense) consisted of the following as of June 30, 2021 and 2020 (in thousands): Six Months Ended June 30, 2021 2020 Interest income $ 272 $ 1,331 Other finance (expense) (60 ) (112 ) Total interest and other income $ 212 $ 1,219

Inventories

Inventories	6 Months Ended
	Jun. 30, 2021
Inventory Disclosure [Abstract]
Inventories	Note 5 – Inventories Inventories consist of the following as of June 30, 2021 and December 31, 2020 (in thousands): June 30, 2021 December 31, 2020 Raw materials (1) $ 2,887 $ 1,051 Finished goods 1,560 913 Total inventories $ 4,447 $ 1,964 (1) $1.0 million of raw materials at June 30, 2021 are included within other non-current assets on the condensed consolidated balance sheets

Fair Value Measurements

Fair Value Measurements	6 Months Ended
	Jun. 30, 2021
Fair Value Disclosures [Abstract]
Fair Value Measurements	Note 6 – Fair Value Measurements The Company follows authoritative accounting guidance, which among other things, defines fair value, establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, a three-tier fair value hierarchy has been established, which prioritizes the inputs used in measuring fair value as follows: Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2: Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. Level 3: Unobservable inputs that reflect the reporting entity ’ The carrying amounts of the Company ’ Assets and liabilities measured at fair value on a recurring basis based on Level 1 and Level 2 fair value measurement criteria as of June 30, 2021 are as follows (in thousands): Fair Value Measurements Using Quoted Prices Significant in Active Other Balance as of Markets for Observable June 30, Identical Assets Inputs 2021 (Level 1) (Level 2) Marketable securities: US government $ 35,585 $ 35,585 $ — Corporate bonds 12,230 — 12,230 Commercial paper 10,984 — 10,984 Money market funds (1) 21,835 21,835 — Certificates of deposit (2) 10,202 — 10,202 Total marketable securities $ 90,836 $ 57,420 $ 33,416 ( 1) Included within cash and cash equivalents on the condensed consolidated balance sheets. ( 2 ) $3.0 million included within cash and cash equivalents on the condensed consolidated balance sheets. Assets and liabilities measured at fair value on a recurring basis based on Level 1 and Level 2 fair value measurement criteria as of December 31, 2020 are as follows (in thousands): Fair Value Measurements Using Quoted Prices Significant in Active Other Balance as of Markets for Observable December 31, Identical Assets Inputs 2020 (Level 1) (Level 2) Marketable securities: US government $ 29,186 $ 29,186 $ — Corporate bonds 21,861 — 21,861 Money market funds (1) 39,744 39,744 — Total marketable securities $ 90,791 $ 68,930 $ 21,861 (1) Included within cash and cash equivalents on the condensed consolidated balance sheets. The Company ’

Marketable Securities

Marketable Securities	6 Months Ended
	Jun. 30, 2021
Investments Debt And Equity Securities [Abstract]
Marketable Securities	Note 7 – Marketable Securities The following table summarizes the Company’s marketable securities as of June 30, 2021 (in thousands): Amortized Cost Basis Unrealized Gains Unrealized Losses Fair Value Marketable securities: US government $ 35,541 $ 44 $ — $ 35,585 Corporate bonds 12,226 4 — 12,230 Commercial paper 10,986 — (2 ) 10,984 Money market funds (1) 21,835 — — 21,835 Certificates of deposit (2) 10,203 — (1 ) 10,202 Total marketable securities $ 90,791 $ 48 $ (3 ) $ 90,836 ( 1) Included within cash and cash equivalents on the condensed consolidated balance sheets ( 2 ) $3.0 million included within cash and cash equivalents on the condensed consolidated balance sheets. The Company classifies its marketable securities as available-for-sale and they consist of all debt securities. The amortized cost basis as of June 30, 2021 includes $0.2 million of accrued interest receivable . realized gains and losses on available-for-sale debt securities are included as a component of comprehensive loss. As of June 30, 2021, the aggregate fair value of marketable securities held by the Company in an unrealized loss position was $40.2 million which consisted of 24 securities. The unrealized loss was driven by investments in commercial paper and certificates of deposit which are measured at fair value based on bid price and purchased at ask price (bid-ask spread). The Company does not expect to settle the debentures at a price less than the amortized cost basis of the investment; the Company expects to recover the entire amortized cost basis of the security. In accordance with the Company’s general investment strategy, the Company does not intend to sell the investments before maturity. As of June 30, 2021, the Company believes the cost basis for its marketable securities were recoverable in all material aspects and no credit impairments were recognized in the period. The Company’s marketable securities as of June 30, 2021 mature at various dates through February 2022. The fair values of marketable securities by contractual maturity consist of the following (in thousands): June 30, 2021 December 31, 2020 Maturities within one year $ 82,546 $ 88,898 Maturities after one year through three years 8,290 1,893 Total marketable securities $ 90,836 $ 90,791

Property and Equipment

Property and Equipment	6 Months Ended
	Jun. 30, 2021
Property Plant And Equipment [Abstract]
Property and Equipment	Note 8 – Property and Equipment Property and equipment, consists of the following as of June 30, 2021 and December 31, 2020 (in thousands): June 30, 2021 December 31, 2020 Laboratory equipment $ 355 $ 333 Computer equipment and software 1,982 1,676 Furniture 598 597 Leasehold improvements 617 609 Manufacturing equipment 245 226 3,797 3,441 Less: accumulated depreciation and amortization (1,796 ) (1,395 ) Property and equipment, net $ 2,001 $ 2,046 Depreciation and amortization expense was $0.2 million and $0.4 million for the three and six months ended June 30, 2021 and $0.1 million and $0.2 million for the three and six months ended June 30, 2020.

Prepaid Forward Obligation

Prepaid Forward Obligation	6 Months Ended
	Jun. 30, 2021
Prepaid Forward Obligation [Abstract]
Prepaid Forward Obligation	Note 9 – In March 2021, the Company entered into a prepaid forward agreement with RTW Investments (“RTW”). Under the terms of the RTW Transaction, the Company received $75.0 million ($72.5 million net of transactions costs) to support the continued launch of Jelmyto Jelmyto Jelmyto Jelmyto Jelmyto In addition, subject to FDA approval of UGN-102, RTW is entitled to receive tiered, future cash payments based on aggregate worldwide annual net product sales of UGN-102 in an amount equal to: (i) 2.5% of annual net sales up to $200 million, (ii) 1.0% of annual net sales for annual net sales between $200 million and $300 million, and (iii) 0.5% of annual net sales for annual net sales above $300 million. If the Company does not receive FDA approval for UGN-102 by a specified date, the future cash payments to RTW with respect to aggregate worldwide annual net sales of Jelmyto Jelmyto In accordance with the prepaid forward agreement, the Company will be required to make payments of amounts owed to RTW each calendar quarter, through and until the quarter in which the aggregate cash payments received by RTW are equal to or greater than $300 million. As security for the payment and fulfilment of these amounts throughout the arrangement, the Company has granted RTW a first priority security interest in Jelmyto In May 2021, following the receipt of necessary regulatory approvals, the Company received the $75.0 million prepaid forward payment ($72.5 million net of transaction costs) from RTW and recognized an associated prepaid forward obligation liability. The subsequent measurement for the liability follows the accounting principles as defined in ASC 835-30, “Imputation of Interest”; each period the Company makes a payment to RTW, and recognizes expense related to financing on the prepaid forward obligation based on an imputed rate derived from the expected future payments. The Company uses a prospective approach for reassessing the effective rate in which a new rate is computed each period based on the current carrying value of the obligation and the revised estimated future payments. Changes in future payments from previous estimates are included in the future financing expense on a prospective basis. The Company does not expect to make any principal payments in the next 12 months. The following table shows the activity with respect to the carrying value of the prepaid forward liability, in thousands: Prepaid forward obligation at closing of RTW Transaction $ 75,000 Capitalized closing costs (2,528 ) Financing on prepaid forward obligation 3,120 Expected payments (790 ) Carrying value of prepaid forward obligation as of June 30, 2021 $ 74,802

Leases

Leases	6 Months Ended
	Jun. 30, 2021
Leases [Abstract]
Leases	Note 10 – Leases Operating Leases The Company has the following office and laboratory facility leases: • In April 2016, UPL signed an addendum to its November 2014 lease agreement for the Company’s executive offices located in Israel, in order to increase the office space rented and to extend the rent period until 2019. In March 2019, UPL utilized the agreement extension option and extended the rent period for additional three years until August 2022. • In September 2017, UPI entered into a new lease agreement for its office space in New York, which the Company previously used as its headquarters. The lease agreement commenced in October 2017 and terminated in February 2021. • In April 2018, UPI entered into a new lease agreement for an office in Los Angeles, California. The lease commencement date was July 10, 2018 and terminates in March 2024. The landlord provided a tenant allowance for leasehold improvements of $0.2 million that was accounted for as a lease incentive. The Company’s remaining contractual obligation under this lease is approximately $0.8 million as of June 30, 2021. In November 2019, UPI entered into a sublease for this office space, with a lease commencement date of January 1, 2020 and continuing until the end of the lease term in March 2024. The subtenants exercised their early access clause and moved into the premises at the end of November 2019. The remaining rental payments to be received over the lease term is approximately $0.7 million as of June 30, 2021 . The Company accounts for the sublease as on operating lease in accordance with ASC 842-10-25-2 and ASC 842-10-25-3. The main lease was considered for impairment and the amount was determined to be immaterial. • In November 2019, UPI entered into a new lease agreement for an office in Princeton, New Jersey, which the Company now uses as its headquarters. The lease commencement date was November 29, 2019 and the lease term is 38 months. The Company’s remaining contractual obligation under this lease is approximately $0.9 million as of June 30, 2021. In addition, the Company has other operating office equipment and vehicle leases. The Company’s operating leases may require minimum rent payments, contingent rent payments adjusted periodically for inflation, or rent payments equal to the greater of a minimum rent or contingent rent. The Company’s leases do not contain any residual value guarantees or material restrictive covenants. The Company’s leases expire at various dates from 2021 through 2023, with varying renewal and termination options. The components of lease cost for the three and six months ended June 30, 2021 were as follows (in thousands) Three Months Ended June 30, Six Months Ended June 30, 2021 2020 2021 2020 Operating lease cost $ 260 $ 428 $ 527 $ 858 Sublease income $ (56 ) $ (56 ) $ (112 ) (112 ) Variable lease cost 14 30 36 86 $ 218 $ 402 $ 451 $ 832 The amounts recognized as of June 30, 2021 and December 31, 2020 were as follows (in thousands): June 30, 2021 December 31, 2020 Right of use asset $ 1,653 $ 2,158 Long-term lease liabilities 922 1,497 Other current liabilities 1,089 1,202 As of June 30, 2021, no impairment losses have been recognized to date. Supplemental information related to leases for the periods reported is as follows (in thousands): Six Months Ended June 30, 2021 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases 2,445 Right-of-use assets obtained in exchange for new operating lease liabilities 135 Weighted-average remaining lease term of operating leases 1.91 years Weighted-average discount rate of operating leases 5.43% Subleases As of June 30, 2021, undiscounted cash flows to be received under the Company’s operating sublease on an annual basis were as follows (in thousands): Operating Leases Years ending December 31, Remainder of 2021 $ 117 2022 243 2023 251 2024 49 2025 — 2026 and thereafter — $ 660 Sublease income is recognized net within operating expense. Sublease income for the three and six months ended June 30, 2021 was as follows (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2021 2020 2021 2020 Sublease income from fixed lease payments $ 56 $ 56 $ 112 $ 112

Revenue from Product Sales

Revenue from Product Sales	6 Months Ended
	Jun. 30, 2021
Revenue From Contract With Customer [Abstract]
Revenue from Product Sales	Note 11 – Revenue From Product Sales Net product sales consist of the following for the three and six months ended June 30, 2021 (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2021 2020 2021 2020 Jelmyto $ 13,032 $ 372 $ 20,517 $ 372

License and Collaboration Agree

License and Collaboration Agreements	6 Months Ended
	Jun. 30, 2021
Liscense Agreement [Abstract]
License and Collaboration Agreements	Note 12 – License and Collaboration Agreements Allergan/AbbVie Agreement In October 2016, the Company entered into the Allergan/AbbVie Agreement and granted Allergan (now part of AbbVie) an exclusive worldwide license to research, develop, manufacture and commercialize pharmaceutical products that contain RTGel ® Under the Allergan/AbbVie Agreement , Allergan is solely responsible , at its expense, for developing, obtaining regulatory approvals for and commercializing the Licensed Products on a worldwide basis . Allergan is obligated to pay the Company a tiered royalty in the low single digits based on worldwide annual net sales of Licensed Products, subject to certain reductions for the market entry of competing products and/or loss of the Company’s patent coverage of Licensed Products. The Company is responsible for payments to any third party for certain RTGel -related third-party intellectual properties. In August 2017, the Company announced that Allergan had submitted an IND to the FDA in order to be able to commence clinical trials in the United States using an RTGel RTGel In August 2020, the Company announced that the Phase 2 APOLLO trial did not meet the primary endpoint, it is believed to be the result of BOTOX not effectively permeating the urothelium. Agenus Agreement In November 2019, the Company entered into a license agreement with Agenus Inc., pursuant to which Agenus granted to the Company an exclusive, worldwide (not including Argentina, Brazil, Chile, Colombia, Peru, Venezuela and their respective territories and possessions), royalty-bearing, sublicensable license under Agenus’s intellectual property rights to develop, make, use, sell, import, and otherwise commercialize products incorporating a proprietary antibody of Agenus known as AGEN1884 for the treatment of cancers of the urinary tract via intravesical delivery. AGEN1884 is an anti-CTLA-4 antagonist that is currently being evaluated by Agenus as a monotherapy in PD-1 refractory patients and in combination with Agenus’ anti-PD-1 antibody in solid tumors. Initially, the Company plans to develop AGEN1884 in combination with UGN-201 for the treatment of high-grade NMIBC. Pursuant to the license agreement, the Company paid Agenus an upfront fee of $10.0 million and has agreed to pay Agenus up to $115.0 million upon achieving certain clinical development and regulatory milestones, up to $85.0 million upon achieving certain commercial milestones, and royalties on net sales of licensed products in the 14%-20% range. The Company will be responsible for all development and commercialization activities. Under the terms of the license agreement, Agenus has agreed to use commercially reasonable efforts to supply AGEN1884 to the Company for use in preclinical studies or clinical trials. Unless earlier terminated in accordance with the terms of the license agreement, the license agreement will expire on a product-by-product and country-by-country basis at the later of (a) the expiration of the last to expire valid claim of a licensed patent right that covers the licensed product in such country or (b) 15 years after the first commercial sale of the licensed product in such country. The Company may terminate the license agreement for convenience upon 180 days’ written notice to Agenus. Either party may terminate the license agreement upon 60 days’ notice to the other party if, prior to the first commercial sale of a licensed product, the Company substantially ceases to conduct development activities of the licensed products for nine consecutive months (and during such period, Agenus has complied with its obligations under the license agreement) other than in response to a requirement of an applicable regulatory authority or an event outside of the Company’s control. In addition, either party may terminate the license agreement in the event of an uncured material breach of the other party. MD Anderson Agreement In January 2021, the Company announced that it entered into a three-year strategic research collaboration agreement with MD Anderson focusing on UGN-302 as an investigational treatment for high-grade NMIBC. Under the agreement, MD Anderson and the Company will collaborate on the design and conduct of non-clinical and clinical studies with oversight from a joint steering committee. The Company will provide funding, developmental candidates, and other support. Pursuant to the agreement, the Company makes bi-annual payments to MD Anderson fund the collaboration. As of June 30, 2021, the Company has made payments to MD Anderson of $ .

Shareholders' Equity

Shareholders' Equity	6 Months Ended
	Jun. 30, 2021
Equity [Abstract]
Shareholders' Equity	Note 13 – Shareholders’ Equity The Company had 100.0 million ordinary shares authorized for issuance as of June 30, 2021 and December 31, 2020. The Company had 22.4 million and 22.2 million ordinary shares issued and outstanding as of June 30, 2021 and December 31, 2020, respectively. Each d w (the “Board”)

Share-Based Compensation

Share-Based Compensation	6 Months Ended
	Jun. 30, 2021
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Share-Based Compensation	Note 14 – Share-Based Compensation In a The b d p l n e Employees are typically granted stock options and/or restricted stock units, or RSUs, upon commencement of employment. Also, eligible employees may receive an annual grant of options or RSUs. Non-employee members of the Board typically receive a grant of RSUs and/or stock options annually. The term of any option granted under the Plan cannot exceed 10 years. Options shall not have an exercise price less than 100% of the fair market value of the Company’s ordinary shares on the grant date, and generally vest over a period of three years. If the individual possesses more than 10% of the combined voting power of all classes of equity of the Company, the exercise price shall not be less than 110% of the fair market value of an ordinary share of stock on the date of grant. The Company’s RSU and option grants provide for accelerated or continued vesting in certain circumstances as defined in the plans and related grant agreements, including a termination in connection with a change in control. RSUs generally vest in a 33% increment upon the first anniversary of grant, and in either equal quarterly or annual amounts for the two years following the one-year anniversary of the grant date. Options generally vest in a 33% increment upon the first anniversary of the grant date, and in either equal quarterly or annual amounts for the two years following the one-year anniversary of the grant date. The a mix of the Company’s historical volatility, and c e In March 2017, the Board adopted the 2017 Equity Incentive Plan (the "2017 Plan"), which was approved by the shareholders in April 2017. The 2017 Plan provides for the grant of stock options, stock appreciation rights, restricted stock awards, RSU awards, performance share awards, performance cash awards, and other forms of share awards to the Company's employees, directors and consultants. The maximum number of ordinary shares that was initially authorized for issuance under the 2017 Plan is 1,400,000. In May 2019, the Company adopted the UroGen Pharma Ltd. 2019 Inducement Plan (the “Inducement Plan”). Under the Inducement Plan, the Company is authorized to issue up to 900,000 ordinary shares pursuant to awards issued under the Inducement Plan. The only persons eligible to receive grants of Awards (as defined below) under the Inducement Plan are individuals who satisfy the standards for inducement grants under Nasdaq Marketplace Rule 5635(c)(4) or 5635(c)(3) and the related guidance under Nasdaq IM 5635-1, including individuals who were not previously an employee or director of the Company or are following a bona fide period of non-employment, in each case as an inducement material to such individual’s agreement to enter into employment with the Company. Under the Inducement Plan, an “Award” is a nonstatutory stock option, restricted stock unit or other right to receive ordinary shares pursuant to the Inducement Plan. The p condensed consolidated For the Three Months Ended June 30, Six Months Ended June 30, 2021 2020 2021 2020 Research and development expense $ 1,041 $ 1,570 $ 2,148 $ 3,513 Selling, general and administrative expense 5,005 5,549 10,093 11,223 $ 6,046 $ 7,119 $ 12,241 $ 14,736 The total unrecognized compensation cost of options and RSUs at June 30, 2021 is $27.7 million with a weighted average recognition period of 1.78 years.

Income Taxes

Income Taxes	6 Months Ended
	Jun. 30, 2021
Income Tax Disclosure [Abstract]
Income Taxes	Note 15 – Income Taxes UroGen Pharma Ltd. The Company has a liability for uncertain tax positions of $2.7 million as of June 30, 2021, for tax positions relating to transfer pricing between affiliated entities. The Company recognizes interest accrued and penalties related to uncertain tax positions as a component of income tax expense. As of June 30, 2021, the Company’s liability for uncertain tax positions includes $0.7 million of interest and penalties accrued during 2020. The Company operates on a global basis and is subject to tax laws and regulations in the U.S. and Israel. The estimate of the Company’s tax liabilities relating to uncertain tax positions requires management to assess uncertainties and to make judgments about the application of complex tax laws and regulations, expectations regarding the outcome of tax authority examinations, as well as the ultimate measurement of potential liabilities. The uncertain tax positions are reviewed quarterly and adjusted as events occur that could affect potential liabilities for additional taxes, including lapsing of applicable statutes of limitations, correspondence with tax authorities, proposed assessments by tax authorities, identification of new issues, and issuance of new legislation or regulations. The Company believes that adequate amounts of tax have been provided in income tax expense for any adjustments that may result from its uncertain tax positions. Based upon the information currently available, the Company does not reasonably expect changes in its existing uncertain tax positions in the next 12 months and has recorded the gross uncertain tax positions as a long-term liability.

Related Parties

Related Parties	6 Months Ended
	Jun. 30, 2021
Related Party Transactions [Abstract]
Related Parties	Note 16 – Related Parties There were no related party transactions for the six months ended June 30, 2021 or 2020.

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2021
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 17 – Commitments and Contingencies In the normal course of business, the Company enters into contracts that contain a variety of indemnifications with its employees, licensors, suppliers and service providers. Further, the Company indemnifies its directors and officers who are, or were, serving at the Company ’ ’ Grants from the Israeli Innovation Authority in Israel (“IIA”) The Company has received grants from the IIA for research and development funding. Up until 2007, the IIA participation in the funding of the Company’s operations was by grants provided to Granot Ventures, a government supported technology incubator, as part of the Israeli Ministry of Industry and Commerce Director General Directive 8.2. Since 2008, the funding was provided directly to Company. On January 12, 2020, the IIA approved the Company's request to unwind its obligation to the IIA regarding grants that were loaned to the Company between January 2004 and September 2016. The total payment under the IIA approval, net of the royalties already paid, $6.6 million, was fully paid during the first quarter of 2020 and recognized as research and development expense. Based on this payment, the Company will have full freedom to transfer IIA-funded technology or manufacture products developed with IIA-funded technology outside of the State of Israel. Other than the commitment to continue at least 75% of its based R&D jobs in Israel (at the time of settlement) for a period of at least three years, all other obligations with the IIA ceased to exist as per the agreement. Leases See Note 10 for further discussion regarding lease commitments.

Subsequent Events

Subsequent Events	6 Months Ended
	Jun. 30, 2021
Subsequent Events [Abstract]
Subsequent Events	Note 18 – Subsequent Events The Company has evaluated and determined there were no subsequent events through August 4, 2021.

Significant Accounting Polici_2

Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2021
Accounting Policies [Abstract]
Principles of Consolidation	Principles of Consolidation The condensed consolidated financial statements include the accounts of UPL and its subsidiary, UPI. Intercompany balances and transactions have been eliminated during consolidation.
Use of Estimates	Use of Estimates The U.S. a i i n a critical estimates relate i
Functional Currency	Functional The p l Accordingly, l n i a condensed
Cash and Cash Equivalents; Marketable Securities	Cash and Cash Equivalents; Marketable Securities The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents. Cash and cash equivalents consist primarily of money market funds and bank money market accounts and are stated at cost, which approximates fair value. Cash and cash equivalents and marketable securities totaled $129.3 million as of June 30, 2021. The Company classifies its marketable securities as available-for-sale in accordance with the Financial Accounting Standards Board (“ Short-term investments are valued using models or other valuation methodologies that use Level 2 inputs. These models are primarily industry-standard models that consider various assumptions, including time value, yield curve, volatility factors, default rates, current market and contractual prices for the underlying financial instruments, as well as other relevant economic measures. The majority of these assumptions are observable in the marketplace, can be derived from observable data or are supported by observable levels at which transactions are executed in the marketplace. For individual debt securities classified as available-for-sale securities where there has been a decline in fair value below amortized cost, the Company determines whether the decline resulted from a credit loss or other factors. The Company records impairment relating to credit losses through an allowance for credit losses, limited by the amount that the fair value is less than the amortized cost basis. Impairment that has not been recorded through an allowance for credit losses is recorded through other comprehensive income, net of applicable taxes.
Concentration of Credit Risk	Concentration of Credit Risk Financial instruments, which potentially subject the Company to significant concentrations of credit risk, consist primarily of cash and cash equivalents and marketable securities. The primary objectives for the Company ’ The Company ’ The Company’s product sales are recognized through the Company's arrangement with a single customer, a third-party national specialty distributor. The Company assesses the need for an allowance for doubtful accounts primarily based on creditworthiness, historical payment experience and general economic conditions. The Company has not experienced any credit losses related to this customer and has not currently recognized any allowance for doubtful accounts.
Income Taxes	Income Taxes The Company provides for income taxes based on pretax income, if any, and applicable tax rates available in the various jurisdictions in which it operates, including Israel and the U.S. deferred l e n s a a The n
Inventory	Inventory The Company capitalizes inventory costs related to products to be sold in the ordinary course of business. The Company makes a determination of capitalizing inventory costs for a product based on, among other factors, status of regulatory approval, information regarding safety, efficacy and expectations relating to commercial sales and recoverability of costs. For Jelmyto The Company values its inventory at the lower of cost or net realizable value. The Company measures inventory approximating actual cost under a first-in, first-out basis. The Company assesses recoverability of inventory each reporting period to determine any write down to net realizable value resulting from excess or obsolete inventories .
Property and Equipment	Property and Equipment Property and equipment are recorded at historical cost, net of accumulated depreciation, amortization and, if applicable, impairment charges. The Company reviews its property and equipment assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Property and equipment are depreciated over the following useful lives (in years): Useful Lives Computers and software 3 Laboratory equipment 3-6.5 Furniture 5-16.5 Manufacturing equipment 2 Leasehold improvements are amortized on a straight-line basis over the shorter of their estimated useful lives or lease terms. See Note 8 for further discussion regarding property and equipment.
Prepaid Forward Obligation	Prepaid Forward Obligation The Company is party to a transaction with RTW Investments (the “RTW Transaction”) in which the Company received funds to support the continued launch of Jelmyto Jelmyto
Leases	Leases The Company is a lessee in several noncancelable operating leases, primarily for office space, office equipment and vehicles. The Company currently has no finance leases. The Company accounts for leases in accordance with ASC Topic 842, “Leases” . Lease expense is recognized on a straight-line basis for operating leases. Variable lease payments associated with the Company’s leases are recognized when the event, activity, or circumstance in the lease agreement on which those payments are assessed occurs. Variable lease payments are presented as operating expense on the condensed consolidated statements of operations in the same line item as expense arising from fixed lease payments. The Company’s lease terms may include options to extend the lease. The lease extensions are included in the measurement of the right of use asset and lease liability when it is reasonably certain that it will exercise that option. Because most of the Company’s leases do not provide an implicit rate of return, an incremental borrowing rate is used based on the information available at the commencement date in determining the present value of lease payments on an individual lease basis. The Company’s incremental borrowing rate for a lease is the rate of interest it would have to pay on a collateralized basis to borrow an amount equal to the lease payments under similar terms. ROU assets for operating leases are periodically reviewed for impairment losses under ASC 360-10, “Property, Plant, and Equipment”, to determine whether an ROU asset is impaired, and if so, the amount of the impairment loss to recognize.
Revenue	Revenue Product sales from Jelmyto Jelmyto
Research and Development Expense	Research and Development Expense Research and development costs are expensed as incurred and consist primarily of the cost of salaries, share-based compensation expense, payroll taxes and other employee benefits, subcontractors and materials used for research and development activities, including nonclinical studies, clinical trials, manufacturing costs and professional services. The costs of services performed by others in connection with the research and development activities of the Company, including research and development conducted by others on behalf of the Company, shall be included in research and development costs and expensed as the contracted work is performed. The Company accrues for costs incurred as the services are being provided by monitoring the status of the trial or project and the invoices received from its external service providers. The Company adjusts its accrual as actual costs become known. Where contingent milestone payments are due to third parties under research and development arrangements or license agreements, the milestone payment obligations are expensed when the milestone results are achieved.
Selling General and Administrative Expense	Selling General and Administrative Expense Selling, general and administrative expense consists primarily of personnel costs (including share-based compensation related to directors, employees and consultants). Other significant costs include commercial, medical affairs, external professional service costs, facility costs, accounting and audit services, legal services, and other consulting fees. Selling, general and administrative costs are expensed as incurred, and the Company accrues for services provided by third parties related to the above expenses by monitoring the status of services provided and receiving estimates from its service providers and adjusting its accruals as actual costs become known.
Share-Based Compensation	Share-Based Compensation Share-based compensation cost is measured at the grant date based on the fair value of the award and is recognized as expense over the required service period, which is equal to the vesting period. The fair value of options is determined using the Black-Scholes option-pricing model. The fair value of a restricted stock unit (“RSU”) equaled the closing price of the Company’s ordinary shares on the grant date. The Company accounts for forfeitures as they occur in accordance with ASC Topic 718, “Compensation—Stock Compensation”. The s n g
Net Loss per Ordinary Share	Net Loss per Ordinary Share Basic net loss per share is computed by dividing the net loss attributable to ordinary shareholders by the weighted-average number of ordinary shares outstanding. Diluted net loss per share is computed similarly to basic net loss per share except that the denominator is increased to include the number of additional ordinary shares that would have been outstanding if the potential ordinary shares had been issued and if the additional ordinary shares were dilutive. For all periods presented, potentially dilutive securities are excluded from the computation of fully diluted loss per share as their effect is anti-dilutive.
Recently Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements The Company has reviewed the Accounting Standards Updates recently issued by the Financial Accounting Standards Board, and determined that they are not applicable to the Company.

Significant Accounting Polici_3

Significant Accounting Policies (Tables)	6 Months Ended
	Jun. 30, 2021
Accounting Policies [Abstract]
Property and Equipment Useful Lives	Property and equipment are depreciated over the following useful lives (in years): Useful Lives Computers and software 3 Laboratory equipment 3-6.5 Furniture 5-16.5 Manufacturing equipment 2

Other Financial Information (Ta

Other Financial Information (Tables)	6 Months Ended
	Jun. 30, 2021
Other Financial Information [Abstract]
Schedule of Accounts Payable and Accrued Expense	Accounts payable and accrued expense consists of the following as of June 30, 2021 and December 31, 2020 (in thousands): June 30, 2021 December 31, 2020 Accounts payable $ 4,830 $ 3,271 Accrued sales reserves 712 382 Accrued clinical expense 1,256 1,359 Accrued research and development expense 859 1,356 Accrued selling, general and administrative expense 1,585 2,440 Accrued other expense 1,100 1,215 Total accounts payable and accrued expense $ 10,342 $ 10,023
Schedule of Interest and Other Income (Expense)	Interest and other income (expense) consisted of the following as of June 30, 2021 and 2020 (in thousands): Six Months Ended June 30, 2021 2020 Interest income $ 272 $ 1,331 Other finance (expense) (60 ) (112 ) Total interest and other income $ 212 $ 1,219

Inventories (Tables)

Inventories (Tables)	6 Months Ended
	Jun. 30, 2021
Inventory Disclosure [Abstract]
Summary of Inventories	Inventories consist of the following as of June 30, 2021 and December 31, 2020 (in thousands): June 30, 2021 December 31, 2020 Raw materials (1) $ 2,887 $ 1,051 Finished goods 1,560 913 Total inventories $ 4,447 $ 1,964 (1) $1.0 million of raw materials at June 30, 2021 are included within other non-current assets on the condensed consolidated balance sheets

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	6 Months Ended
	Jun. 30, 2021
Fair Value Disclosures [Abstract]
Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis	Assets and liabilities measured at fair value on a recurring basis based on Level 1 and Level 2 fair value measurement criteria as of June 30, 2021 are as follows (in thousands): Fair Value Measurements Using Quoted Prices Significant in Active Other Balance as of Markets for Observable June 30, Identical Assets Inputs 2021 (Level 1) (Level 2) Marketable securities: US government $ 35,585 $ 35,585 $ — Corporate bonds 12,230 — 12,230 Commercial paper 10,984 — 10,984 Money market funds (1) 21,835 21,835 — Certificates of deposit (2) 10,202 — 10,202 Total marketable securities $ 90,836 $ 57,420 $ 33,416 ( 1) Included within cash and cash equivalents on the condensed consolidated balance sheets. ( 2 ) $3.0 million included within cash and cash equivalents on the condensed consolidated balance sheets. Assets and liabilities measured at fair value on a recurring basis based on Level 1 and Level 2 fair value measurement criteria as of December 31, 2020 are as follows (in thousands): Fair Value Measurements Using Quoted Prices Significant in Active Other Balance as of Markets for Observable December 31, Identical Assets Inputs 2020 (Level 1) (Level 2) Marketable securities: US government $ 29,186 $ 29,186 $ — Corporate bonds 21,861 — 21,861 Money market funds (1) 39,744 39,744 — Total marketable securities $ 90,791 $ 68,930 $ 21,861 (1) Included within cash and cash equivalents on the condensed consolidated balance sheets.

Marketable Securities (Tables)

Marketable Securities (Tables)	6 Months Ended
	Jun. 30, 2021
Investments Debt And Equity Securities [Abstract]
Summary of Marketable Securities	The following table summarizes the Company’s marketable securities as of June 30, 2021 (in thousands): Amortized Cost Basis Unrealized Gains Unrealized Losses Fair Value Marketable securities: US government $ 35,541 $ 44 $ — $ 35,585 Corporate bonds 12,226 4 — 12,230 Commercial paper 10,986 — (2 ) 10,984 Money market funds (1) 21,835 — — 21,835 Certificates of deposit (2) 10,203 — (1 ) 10,202 Total marketable securities $ 90,791 $ 48 $ (3 ) $ 90,836 ( 1) Included within cash and cash equivalents on the condensed consolidated balance sheets ( 2 ) $3.0 million included within cash and cash equivalents on the condensed consolidated balance sheets.
Summary of Fair Values of Marketable Securities by Contractual Maturity	The fair values of marketable securities by contractual maturity consist of the following (in thousands) June 30, 2021 December 31, 2020 Maturities within one year $ 82,546 $ 88,898 Maturities after one year through three years 8,290 1,893 Total marketable securities $ 90,836 $ 90,791

Property and Equipment (Tables)

Property and Equipment (Tables)	6 Months Ended
	Jun. 30, 2021
Property Plant And Equipment [Abstract]
Schedule of Property and Equipment	Property and equipment, consists of the following as of June 30, 2021 and December 31, 2020 (in thousands): June 30, 2021 December 31, 2020 Laboratory equipment $ 355 $ 333 Computer equipment and software 1,982 1,676 Furniture 598 597 Leasehold improvements 617 609 Manufacturing equipment 245 226 3,797 3,441 Less: accumulated depreciation and amortization (1,796 ) (1,395 ) Property and equipment, net $ 2,001 $ 2,046

Prepaid Forward Obligation (Tab

Prepaid Forward Obligation (Tables)	6 Months Ended
	Jun. 30, 2021
Prepaid Forward Obligation [Abstract]
Schedule of Activity Respect to Carrying Value of Prepaid Forward Liability	The following table shows the activity with respect to the carrying value of the prepaid forward liability, in thousands: Prepaid forward obligation at closing of RTW Transaction $ 75,000 Capitalized closing costs (2,528 ) Financing on prepaid forward obligation 3,120 Expected payments (790 ) Carrying value of prepaid forward obligation as of June 30, 2021 $ 74,802

Leases (Tables)

Leases (Tables)	6 Months Ended
	Jun. 30, 2021
Leases [Abstract]
Components of Lease Cost	The components of lease cost for the three and six months ended June 30, 2021 were as follows (in thousands) Three Months Ended June 30, Six Months Ended June 30, 2021 2020 2021 2020 Operating lease cost $ 260 $ 428 $ 527 $ 858 Sublease income $ (56 ) $ (56 ) $ (112 ) (112 ) Variable lease cost 14 30 36 86 $ 218 $ 402 $ 451 $ 832
Schedule of Amounts Recognized	The amounts recognized as of June 30, 2021 and December 31, 2020 were as follows (in thousands): June 30, 2021 December 31, 2020 Right of use asset $ 1,653 $ 2,158 Long-term lease liabilities 922 1,497 Other current liabilities 1,089 1,202
Schedule of Supplemental Information Related to Leases	Supplemental information related to leases for the periods reported is as follows (in thousands): Six Months Ended June 30, 2021 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases 2,445 Right-of-use assets obtained in exchange for new operating lease liabilities 135 Weighted-average remaining lease term of operating leases 1.91 years Weighted-average discount rate of operating leases 5.43%
Schedule of Undiscounted Cash Flows to be Received Under Operating Sublease on an Annual Basis	As of June 30, 2021, undiscounted cash flows to be received under the Company’s operating sublease on an annual basis were as follows (in thousands): Operating Leases Years ending December 31, Remainder of 2021 $ 117 2022 243 2023 251 2024 49 2025 — 2026 and thereafter — $ 660
Schedule of Sublease Income Recognized Net within Operating Expenses	Sublease income is recognized net within operating expense. Sublease income for the three and six months ended June 30, 2021 was as follows (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2021 2020 2021 2020 Sublease income from fixed lease payments $ 56 $ 56 $ 112 $ 112

Revenue from Product Sales (Tab

Revenue from Product Sales (Tables)	6 Months Ended
	Jun. 30, 2021
Revenue From Contract With Customer [Abstract]
Schedule of Net Product Sales	Net product sales consist of the following for the three and six months ended June 30, 2021 (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2021 2020 2021 2020 Jelmyto $ 13,032 $ 372 $ 20,517 $ 372

Share-Based Compensation (Table

Share-Based Compensation (Tables)	6 Months Ended
	Jun. 30, 2021
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Schedule of Effect of Share-Based Compensation on Statements of Operations	The p condensed consolidated For the Three Months Ended June 30, Six Months Ended June 30, 2021 2020 2021 2020 Research and development expense $ 1,041 $ 1,570 $ 2,148 $ 3,513 Selling, general and administrative expense 5,005 5,549 10,093 11,223 $ 6,046 $ 7,119 $ 12,241 $ 14,736

Business and Nature of Operat_2

Business and Nature of Operations - Additional Information (Details)	6 Months Ended
	Jun. 30, 2021
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Date of incorporation	2004-04
Date of operating commencement	2016-02

Basis of Presentation - Additit

Basis of Presentation - Addititonal Information (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Accumulated deficit	$ 408,658	$ 356,501

Significant Accounting Polici_4

Significant Accounting Policies - Additional Information (Details) $ in Millions	Jun. 30, 2021USD ($)
Accounting Policies [Abstract]
Total cash and cash equivalents and marketable securities	$ 129.3

Significant Accounting Polici_5

Significant Accounting Policies - Property and Equipment Useful Lives (Details)	6 Months Ended
	Jun. 30, 2021
Computers and Software
Property Plant And Equipment [Line Items]
Property and Equipment, Useful Lives	3 years
Laboratory Equipment | Minimum
Property Plant And Equipment [Line Items]
Property and Equipment, Useful Lives	3 years
Laboratory Equipment | Maximum
Property Plant And Equipment [Line Items]
Property and Equipment, Useful Lives	6 years 6 months
Furniture | Minimum
Property Plant And Equipment [Line Items]
Property and Equipment, Useful Lives	5 years
Furniture | Maximum
Property Plant And Equipment [Line Items]
Property and Equipment, Useful Lives	16 years 6 months
Manufacturing Equipment
Property Plant And Equipment [Line Items]
Property and Equipment, Useful Lives	2 years

Other Financial Information - S

Other Financial Information - Schedule of Accounts Payable and Accrued Expense (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Other Financial Information [Abstract]
Accounts payable	$ 4,830	$ 3,271
Accrued sales reserves	712	382
Accrued clinical expense	1,256	1,359
Accrued research and development expense	859	1,356
Accrued selling, general and administrative expense	1,585	2,440
Accrued other expense	1,100	1,215
Total accounts payable and accrued expense	$ 10,342	$ 10,023

Other Financial Information -_2

Other Financial Information - Schedule of Interest and Other Income (Expense) (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Other Financial Information [Abstract]
Interest income	$ 272	$ 1,331
Other finance (expense)	(60)	(112)
Total interest and other income	$ 212	$ 1,219

Inventories - Schedule of Inven

Inventories - Schedule of Inventories (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Inventory Disclosure [Abstract]
Raw materials	$ 2,887	$ 1,051
Finished goods	1,560	913
Total inventories	$ 4,447	$ 1,964

Inventories - Schedule of Inv_2

Inventories - Schedule of Inventories (Parenthetical) (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Inventory [Line Items]
Raw materials	$ 2,887	$ 1,051
Other Noncurrent Assets
Inventory [Line Items]
Raw materials	$ 1,000

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Details)	6 Months Ended
	Jun. 30, 2021USD ($)
Fair Value Disclosures [Abstract]
Fair value assets, transfers between level 1 to level 2	$ 0
Fair value assets, transfers between level 2 to level 1	0
Fair value liabilities, transfers between level 1 to level 2	0
Fair value liabilities, transfers between level 2 to level 1	0
Fair value assets, transfers into level 3	0
Fair value assets, transfers out of level 3	0
Fair value liabilities, transfers into level 3	0
Fair value liabilities, transfers out of level 3	$ 0

Fair Value Measurements - Summa

Fair Value Measurements - Summary of Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Marketable securities:	$ 90,836	$ 90,791
Fair Value, Measurements, Recurring
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Marketable securities:	90,836	90,791
Fair Value, Measurements, Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1)
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Marketable securities:	57,420	68,930
Fair Value, Measurements, Recurring | Significant Other Observable Inputs (Level 2)
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Marketable securities:	33,416	21,861
Fair Value, Measurements, Recurring | US Government
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Marketable securities:	35,585	29,186
Fair Value, Measurements, Recurring | US Government | Quoted Prices in Active Markets for Identical Assets (Level 1)
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Marketable securities:	35,585	29,186
Fair Value, Measurements, Recurring | Corporate Bonds
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Marketable securities:	12,230	21,861
Fair Value, Measurements, Recurring | Corporate Bonds | Significant Other Observable Inputs (Level 2)
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Marketable securities:	12,230	21,861
Fair Value, Measurements, Recurring | Commercial Paper
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Marketable securities:	10,984
Fair Value, Measurements, Recurring | Commercial Paper | Significant Other Observable Inputs (Level 2)
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Marketable securities:	10,984
Fair Value, Measurements, Recurring | Money Market Funds
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Marketable securities:	21,835	39,744
Fair Value, Measurements, Recurring | Money Market Funds | Quoted Prices in Active Markets for Identical Assets (Level 1)
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Marketable securities:	21,835	$ 39,744
Fair Value, Measurements, Recurring | Certificates of Deposit
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Marketable securities:	10,202
Fair Value, Measurements, Recurring | Certificates of Deposit | Significant Other Observable Inputs (Level 2)
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Marketable securities:	$ 10,202

Fair Value Measurements - Sum_2

Fair Value Measurements - Summary of Assets and Liabilities Measured at Fair Value on a Recurring Basis (Parenthetical) (Details) $ in Millions	Jun. 30, 2021USD ($)
Cash and Cash Equivalents
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Certificates of deposit	$ 3

Marketable Securities - Summary

Marketable Securities - Summary of Marketable Securities (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Marketable securities:
Amortized Cost Basis	$ 90,791
Unrealized Gains	48
Unrealized Losses	(3)
Fair Value	90,836	$ 90,791
US Government
Marketable securities:
Amortized Cost Basis	35,541
Unrealized Gains	44
Fair Value	35,585
Corporate Bonds
Marketable securities:
Amortized Cost Basis	12,226
Unrealized Gains	4
Fair Value	12,230
Commercial Paper
Marketable securities:
Amortized Cost Basis	10,986
Unrealized Losses	(2)
Fair Value	10,984
Money Market Funds
Marketable securities:
Amortized Cost Basis	21,835
Fair Value	21,835
Certificates of Deposit
Marketable securities:
Amortized Cost Basis	10,203
Unrealized Losses	(1)
Fair Value	$ 10,202

Marketable Securities - Summa_2

Marketable Securities - Summary of Marketable Securities (Parenthetical) (Details) $ in Millions	Jun. 30, 2021USD ($)
Cash and Cash Equivalents
Marketable Securities [Line Items]
Certificates of deposit	$ 3

Marketable Securities - Additio

Marketable Securities - Additional Information (Details)	6 Months Ended
	Jun. 30, 2021USD ($)Security
Investments Debt And Equity Securities [Abstract]
Accrued interest receivable	$ 200,000
Available-for-sale debt securities, unrealized gain or loss position	0
Available-for-sale debt securities, unrealized loss position	$ 40,200,000
Available-for-sale debt securities, number of securities in unrealized loss position | Security	24
Other-than-temporary impairment Loss, debt securities, portion recognized in earnings	$ 0

Marketable Securities - Summa_3

Marketable Securities - Summary of Fair Values of Marketable Securities by Contractual Maturity (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Available For Sale Securities Debt Maturities Fair Value [Abstract]
Maturities within one year	$ 82,546	$ 88,898
Maturities after one year through three years	8,290	1,893
Total marketable securities	$ 90,836	$ 90,791

Property and Equipment - Schedu

Property and Equipment - Schedule of Property and Equipment (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Property Plant And Equipment [Line Items]
Property and equipment	$ 3,797	$ 3,441
Less: accumulated depreciation and amortization	(1,796)	(1,395)
Property and equipment, net	2,001	2,046
Laboratory Equipment
Property Plant And Equipment [Line Items]
Property and equipment	355	333
Computers and Software
Property Plant And Equipment [Line Items]
Property and equipment	1,982	1,676
Furniture
Property Plant And Equipment [Line Items]
Property and equipment	598	597
Leasehold Improvements
Property Plant And Equipment [Line Items]
Property and equipment	617	609
Manufacturing Equipment
Property Plant And Equipment [Line Items]
Property and equipment	$ 245	$ 226

Property and Equipment - Additi

Property and Equipment - Additional Information (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Property Plant And Equipment [Abstract]
Depreciation and amortization expense	$ 0.2	$ 0.1	$ 0.4	$ 0.2

Prepaid Forward Obligation - Ad

Prepaid Forward Obligation - Additional Information (Details) - USD ($)	1 Months Ended
	May 31, 2021	Mar. 31, 2021	Jun. 30, 2021
RTW Investments
Research And Development Arrangement Contract To Perform For Others [Line Items]
Upfront fee		$ 75,000,000
Upfront cash payment received net of costs	$ 72,500,000	$ 72,500,000
Percentage of milestone payment receivable on annual net sales one		9.50%
Percentage of milestone payment receivable on annual net sales two		3.00%
Percentage of milestone payment receivable on annual net sales three		1.00%
Possible increase in percentage of milestone payment receivable on annual net sales		3.50%
Threshold amount for quarterly cash payments			$ 300,000,000
Upfront fee received	$ 75,000,000
Expect principal payments in next 12 months			$ 0
RTW Investments | Minimum
Research And Development Arrangement Contract To Perform For Others [Line Items]
Threshold revenue to receive milestone payments two		$ 200,000,000
Threshold revenue to receive milestone payments three		300,000,000
RTW Investments | Maximum
Research And Development Arrangement Contract To Perform For Others [Line Items]
Threshold revenue to receive milestone payments one		200,000,000
Threshold revenue to receive milestone payments two		$ 300,000,000
RTW Investments Subject to FDA Approval
Research And Development Arrangement Contract To Perform For Others [Line Items]
Percentage of milestone payment receivable on annual net sales one		2.50%
Percentage of milestone payment receivable on annual net sales two		1.00%
Percentage of milestone payment receivable on annual net sales three		0.50%
Possible increase in percentage of milestone payment receivable on annual net sales		1.50%
RTW Investments Subject to FDA Approval | Minimum
Research And Development Arrangement Contract To Perform For Others [Line Items]
Threshold revenue to receive milestone payments two		$ 200,000,000
Threshold revenue to receive milestone payments three		300,000,000
RTW Investments Subject to FDA Approval | Maximum
Research And Development Arrangement Contract To Perform For Others [Line Items]
Threshold revenue to receive milestone payments one		200,000,000
Threshold revenue to receive milestone payments two		$ 300,000,000

Prepaid Forward Obligation - Sc

Prepaid Forward Obligation - Schedule of Activity Respect to Carrying Value of Prepaid Forward Liability (Details) $ in Thousands	Jun. 30, 2021USD ($)
Prepaid Forward Obligation [Line Items]
Prepaid forward obligation	$ 74,802
RTW Investments
Prepaid Forward Obligation [Line Items]
Prepaid forward obligation	75,000
Capitalized closing costs	(2,528)
Financing on prepaid forward obligation	3,120
Expected payments	(790)
Carrying value of prepaid forward obligation as of June 30, 2021	$ 74,802

Leases - Additional Information

Leases - Additional Information (Details) - USD ($)	1 Months Ended			3 Months Ended		6 Months Ended
	Nov. 30, 2019	Apr. 30, 2018	Sep. 30, 2017	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Lessee Lease Description [Line Items]
Operating leases, existence of option to extend						true
Operating leases, options to extend lease term, description						UPL signed an addendum to its November 2014 lease agreement for the Company’s executive offices located in Israel, in order to increase the office space rented and to extend the rent period until 2019. In March 2019, UPL utilized the agreement extension option and extended the rent period for additional three years until August 2022
Operating leases, options to extend lease term				3 years		3 years
Operating lease extended lease expiration, month and year						2022-08
Remaining rental payments to be received over the lease term				$ 56,000	$ 56,000	$ 112,000	$ 112,000
Impairment losses on operating leases						$ 0
Minimum
Lessee Lease Description [Line Items]
Lease expiration year						2021
Maximum
Lessee Lease Description [Line Items]
Lease expiration year						2023
New York | UroGen Pharma Inc.
Lessee Lease Description [Line Items]
Lease commencement period, month and year			2017-10
Lease termination period, month and year			2021-02
Los Angeles, California | UroGen Pharma Inc.
Lessee Lease Description [Line Items]
Lease termination period, month and year		2024-03
Lease commencement date		Jul. 10, 2018
Proceeds from tenant allowance		$ 200,000
Remaining contractual obligation				800,000		$ 800,000
Lessee operating sublease commencement date	Jan. 1, 2020
Lessee operating sublease termination period, month and year	2024-03
Remaining rental payments to be received over the lease term						700,000
Princeton, NJ | UroGen Pharma Inc. | Lease Agreement
Lessee Lease Description [Line Items]
Lease commencement date	Nov. 29, 2019
Remaining contractual obligation				$ 900,000		$ 900,000
Lease term	38 months

Leases - Components of Lease Co

Leases - Components of Lease Cost (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Leases [Abstract]
Operating lease cost	$ 260	$ 428	$ 527	$ 858
Sublease income	(56)	(56)	(112)	(112)
Variable lease cost	14	30	36	86
Lease, Cost	$ 218	$ 402	$ 451	$ 832

Leases - Schedule of Amounts Re

Leases - Schedule of Amounts Recognized (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Leases [Abstract]
Right of use asset	$ 1,653	$ 2,158
Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]	Other non-current assets	Other non-current assets
Long-term lease liability	$ 922	$ 1,497
Other current liabilities	$ 1,089	$ 1,202
Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]	Other current liabilities	Other current liabilities

Leases - Schedule of Supplement

Leases - Schedule of Supplemental Information Related to Leases (Details) $ in Thousands	6 Months Ended
	Jun. 30, 2021USD ($)
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases	$ 2,445
Right-of-use assets obtained in exchange for new operating lease liabilities	$ 135
Weighted-average remaining lease term of operating leases	1 year 10 months 28 days
Weighted-average discount rate of operating leases	5.43%

Leases - Schedule of Undiscount

Leases - Schedule of Undiscounted Cash Flows to be Received Under Operating Sublease on an Annual Basis (Details) $ in Thousands	Jun. 30, 2021USD ($)
Leases [Abstract]
Remainder of 2021	$ 117
2022	243
2023	251
2024	49
Lessee operating sublease payments to be received	$ 660

Leases - Schedule of Sublease I

Leases - Schedule of Sublease Income Recognized Net within Operating Expenses (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Leases [Abstract]
Sublease income from fixed lease payments	$ 56	$ 56	$ 112	$ 112

Revenue from Product Sales - Sc

Revenue from Product Sales - Schedule of Net Product Sales (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Revenue From Contract With Customer [Abstract]
Revenue from Contract with Customer Product and Service [Extensible List]	urgn:JelmytosMember	urgn:JelmytosMember	urgn:JelmytosMember	urgn:JelmytosMember
Revenue	$ 13,032	$ 372	$ 20,517	$ 372

License and Collaboration Agr_2

License and Collaboration Agreements - Additional Information (Details) - USD ($)	1 Months Ended	6 Months Ended
	Nov. 30, 2019	Jun. 30, 2021
Agenus Agreement
Research And Development Arrangement Contract To Perform For Others [Line Items]
Upfront fee	$ 10,000,000
Maximum amount payable upon achieving certain clinical development and regulatory milestones	115,000,000
Maximum amount payable upon achieving certain commercial milestones	$ 85,000,000
Agenus Agreement | After First Commercial Sale of Licensed Product
Research And Development Arrangement Contract To Perform For Others [Line Items]
License agreement expiration term	15 years
MD Anderson
Research And Development Arrangement Contract To Perform For Others [Line Items]
Payments recognized through research and development expenses		$ 500,000
Minimum | Agenus Agreement
Research And Development Arrangement Contract To Perform For Others [Line Items]
Royalty ranging on net sales of licensed products	14.00%
Maximum | Agenus Agreement
Research And Development Arrangement Contract To Perform For Others [Line Items]
Royalty ranging on net sales of licensed products	20.00%

Shareholders' Equity - Addition

Shareholders' Equity - Additional Information (Details) - shares	Jun. 30, 2021	Dec. 31, 2020
Equity [Abstract]
Ordinary shares, shares authorized	100,000,000	100,000,000
Ordinary shares, issued	22,354,533	22,167,791
Ordinary shares, outstanding	22,354,533	22,167,791

Share-Based Compensation - Addi

Share-Based Compensation - Additional Information (Details) - USD ($) $ in Millions	Jun. 07, 2021	Jun. 08, 2020	Oct. 12, 2018	Jan. 01, 2018	Mar. 31, 2017	Jun. 30, 2021	May 31, 2019
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Unrecognized compensation cost of options and RSUs						$ 27.7
Expected to be recognized over a weighted average period						1 year 9 months 10 days
Options | Tranche One
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting percentage						33.00%
Restricted Stock Units (RSUs)
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Awards vesting period						2 years
Restricted Stock Units (RSUs) | Tranche One
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting percentage						33.00%
2017 Equity Incentive Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Maximum number of ordinary share issuable under the 2017 incentive plan					1,400,000
Ordinary shares subject to outstanding						3,197,979
Ordinary shares remain available for future awards						752,188
Increase in number of ordinary share issuable under the 2017 incentive plan	400,000	400,000	1,900,000	250,167
Plan | Options
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Awards vesting period						3 years
Combined voting power percentage						10.00%
Ordinary Shares | 2019 Inducement Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of stock options approved for grants							900,000
Ordinary Shares | 2017 Equity Incentive Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Maximum number of ordinary share issuable under the 2017 incentive plan	4,350,167	3,950,167	3,550,167	1,650,167
Maximum | Plan | Options
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Options granted, expected term						10 years
Minimum | Plan | Options
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Exercise price of stock options as percentage of fair market value of shares on grant date						100.00%
Stock options exercise price percentage for individuals possesses more than 10% of the combined voter power						110.00%

Share Based Compensation - Sche

Share Based Compensation - Schedule of Effect of Share-Based Compensation on Condensed Consolidated Statements of Operations (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Share-based compensation	$ 6,046	$ 7,119	$ 12,241	$ 14,736
Research and Development Expense
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Share-based compensation	1,041	1,570	2,148	3,513
Selling, General and Administrative Expense
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Share-based compensation	$ 5,005	$ 5,549	$ 10,093	$ 11,223

Income Taxes - Additional Infor

Income Taxes - Additional Information (Details) $ in Millions	Jun. 30, 2021USD ($)
Income Tax Disclosure [Abstract]
Liability for uncertain tax positions	$ 2.7
Accrued interest and penalties included in liability for uncertain tax positions	$ 0.7

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Details) - IIA - USD ($) $ in Millions	6 Months Ended
	Jun. 30, 2021	Mar. 31, 2020
Commitments And Contingent Liabilities [Line Items]
Royalty amount payable		$ 6.6
Maximum percentage of commitment to continue employment of research and development jobs	75.00%
Maximum term for commitment to continue employment of research and development jobs	3 years